468 related articles for article (PubMed ID: 17010208)
1. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
Zhou S; Wang GP; Liu C; Zhou M
BMC Cancer; 2006 Sep; 6():231. PubMed ID: 17010208
[TBL] [Abstract][Full Text] [Related]
2. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
[TBL] [Abstract][Full Text] [Related]
3. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H
Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830
[TBL] [Abstract][Full Text] [Related]
4. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.
Safwat MD; Habib F; Elayat A; Oweiss N; Reffat S; Algaidi S
Folia Morphol (Warsz); 2009 Aug; 68(3):144-55. PubMed ID: 19722158
[TBL] [Abstract][Full Text] [Related]
5. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer.
Byrnes K; White S; Chu Q; Meschonat C; Yu H; Johnson LW; Debenedetti A; Abreo F; Turnage RH; McDonald JC; Li BD
Ann Surg; 2006 May; 243(5):684-90; discussion 691-2. PubMed ID: 16633004
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Netto GC; Bleil CB; Hilbig A; Coutinho LM
Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
[TBL] [Abstract][Full Text] [Related]
7. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
8. Microvessel density assessment in benign and malignant endometrial changes.
Czekierdowski A; Czekierdowska S; Czuba B; Cnota W; Sodowski K; Kotarski J; Zwirska-Korczala K
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():45-51. PubMed ID: 18955753
[TBL] [Abstract][Full Text] [Related]
9. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma].
Li Q; Zhang B; Peng P
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Dec; 21(24):1114-7. PubMed ID: 18330257
[TBL] [Abstract][Full Text] [Related]
10. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer.
Theodoropoulos VE; Lazaris ACh; Sofras F; Gerzelis I; Tsoukala V; Ghikonti I; Manikas K; Kastriotis I
Eur Urol; 2004 Aug; 46(2):200-8. PubMed ID: 15245814
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
Yao Y; Kubota T; Takeuchi H; Sato K
Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.
Ludovini V; Sidoni A; Pistola L; Bellezza G; De Angelis V; Gori S; Mosconi AM; Bisagni G; Cherubini R; Bian AR; Rodinò C; Sabbatini R; Mazzocchi B; Bucciarelli E; Tonato M; Colozza M
Breast Cancer Res Treat; 2003 Sep; 81(2):159-68. PubMed ID: 14572158
[TBL] [Abstract][Full Text] [Related]
14. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
[TBL] [Abstract][Full Text] [Related]
15. Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer.
Chang Y; Niu W; Lian PL; Wang XQ; Meng ZX; Liu Y; Zhao R
World J Gastroenterol; 2016 Jun; 22(23):5422-9. PubMed ID: 27340359
[TBL] [Abstract][Full Text] [Related]
16. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
Barresi V; Cerasoli S; Vitarelli E; Tuccari G
Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
Gluz O; Wild P; Liedtke C; Kates R; Mendrik H; Ehm E; Artinger V; Diallo-Danebrock R; Ting E; Mohrmann S; Poremba C; Harbeck N; Nitz U; Hartmann A; Gaumann A
Breast Cancer Res Treat; 2011 Apr; 126(3):643-51. PubMed ID: 21318601
[TBL] [Abstract][Full Text] [Related]
18. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma.
Huang C; Huang R; Chang W; Jiang T; Huang K; Cao J; Sun X; Qiu Z
Neoplasma; 2012; 59(1):52-61. PubMed ID: 22082308
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
Raica M; Cimpean AM; Anghel A
Neoplasma; 2007; 54(4):278-84. PubMed ID: 17822316
[TBL] [Abstract][Full Text] [Related]
20. mRNA expression of the angiogenesis markers VEGF and CD105 (endoglin) in human breast cancer.
Gómez-Esquer F; Agudo D; Martínez-Arribas F; Nuñez-Villar MJ; Schneider J
Anticancer Res; 2004; 24(3a):1581-5. PubMed ID: 15274325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
